Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Spruce Biosciences, Inc. SPRB NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$234.00
+232.4%

Spruce Biosciences, Inc. (SPRB) is a Biotechnology company in the Healthcare sector, currently trading at $70.39. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is SPRB = $234 (+232.4% upside).

Valuation: SPRB trades at a trailing Price-to-Earnings (P/E) of -1.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.1.

Net income is $39M (loss), growing at +4%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $736,000 against $43M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 5.17 (strong liquidity). Debt-to-assets is 1.4%. Total assets: $53M.

Analyst outlook: 6 / 11 analysts rate SPRB as buy (55%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 64/100 (Pass), Income ?/100 (Fail).

$234.00
▲ 232.43% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Spruce Biosciences, Inc., the average price target is $234.00, with a high forecast of $283.00, and a low forecast of $160.00.
Highest Price Target
$283.00
Average Price Target
$234.00
Lowest Price Target
$160.00

SPRB SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SPRB

✓
VALUE Pass
100/100
SPRB trades at a trailing Price-to-Earnings (P/E) of -1.3 (S&P 500 average ~25). Forward PEG 0.1 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $234, implying +232.4% from the current price $70. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
30/100
SPRB: -75.7%/yr revenue is, +4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet SPRB: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 5.17 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
SPRB: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 6 / 11 analysts rate SPRB as buy (55%). Analyst consensus target is $234 (+232.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7-1777.5
Volume51.27K
Avg Volume (30D)45.48K
Market Cap$96.58M
Beta (1Y)3.68
Share Statistics
EPS (TTM)-50.83
Shares Outstanding$766.6K
IPO Date2020-10-09
Employees20
CEOJavier Szwarcberg
Financial Highlights & Ratios
Gross Profit$-21K
EBITDA$-36.51M
Net Income$-38.97M
Operating Income$-36.51M
Total Cash$48.91M
Total Debt$736K
Net Debt$-48.17M
Total Assets$53.02M
Price / Earnings (P/E)-1.4
Analyst Forecast
1Y Price Target$259.00
Target High$283.00
Target Low$160.00
Upside+267.9%
Rating ConsensusBuy
Analysts Covering11
Buy 55% Hold 45% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS85209E2081

Price Chart

Track all markets on TradingView
SPRB
Spruce Biosciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
7.00 52WK RANGE 1,777.50

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.30
+3.13%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.72
+1.49%
 XFOR
XFOR
X4 Pharmaceuticals, Inc.
$4.33
+3.10%
 HOOK
HOOK
HOOKIPA Pharma Inc.
$1.11
-1.34%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message